Associate Professor Ed Litton: helping medicine get better

In intensive care, doctors do their best to keep you alive and help you get better. The joint winner of Woodside Early Career Scientist of the Year Ed Litton figures out what 'best' actually is – and proves it.
Rockwell McGellin
Rockwell McGellin
STEM Content Creator
Associate Professor Ed Litton: helping medicine get better
Image credit: Premier’s Science Awards | UWA

Everything doctors do in a hospital is tried and tested. Before they give you a drug or surgical procedure, someone’s got to prove that it’s safe – and that it works.

Associate Professor Ed Litton is one of this year’s Woodside Early Career Scientists of the Year (alongside Dr Arman Siahvashi). He’s a doctor in intensive care at Fiona Stanley Hospital, but also a researcher with UWA. He’s doing that trying and testing.

“Over 10,000 West Australians need intensive care each year,” he says. “In my clinical work, I get to care for them, but it’s also nice to be doing research.

“It’s my way of trying to make sure that I can treat tomorrow’s patient better than I did today.”
Associate Professor Ed Litton
Image credit: Premier’s Science Awards | UWA

Trial by fire

“People hold doctors in incredibly high regard,” Ed says. “They have an assumption that we always know what is best, that somehow we just know which treatments work.”

But doctors don’t have a sixth sense for good treatments. Instead, they rely on evidence, like the data Ed and his teams gather.

Ed specialises in clinical trials. They’re the gruelling, rigorous tests that an experimental treatment has to pass before it becomes … just a regular treatment.

“Clinical trials really are the best and only way we have of providing certainty around whether something we’re doing is truly beneficial or not,” he says.

“And you also identify things that are either useless or, even worse, harmful. It means you remove those harmful treatments from clinical practice, and the ones that are identified as beneficial can be incorporated into the usual clinical care.”

“The challenge is to be able to communicate and explain the role of research in answering questions where we have uncertainty.”

Video credit: Premier’s Science Awards | Department of Jobs, Tourism, Science and Innovation

Planning for a pandemic

For most of us, the COVID-19 pandemic was our first real chance to watch this process in action. For Ed and his teams, it kicked off a trial that took years to come together.

“It takes months and months, sometimes years, to develop a clinical trial to the point where you can begin to recruit patients,” he says.

“By the time we were ready to recruit patients with swine flu, that pandemic had passed. We lost the opportunity not only to do better for our patients at that time but to learn for next time.

But they kept their plans in place, just in case.

“We didn’t know that it was going to be COVID, but we knew that respiratory pandemic infections come along not infrequently. We had to have the infrastructure and knowledge base there ready to go.”

Because that trial was already lined up, it started delivering results fast.

“It’s had tremendous outputs in terms of pretty early on identifying that hydroxychloroquine was not beneficial despite all the hype. It identified that corticosteroids were beneficial, and it identified that interleukin-6 antagonists were beneficial,” he says.

“It’s satisfying to see those research outputs become usual care.”

Ed says that, even though COVID-19 was a tragedy, it was also an amazing chance to see treatments go from anecdotes to evidence to implementation of that evidence.

“The things that would have been considered experimental a year ago are just standard now.”

Science meets medicine

Ed says making research part of his job helps keep fuel his creative side.

“In science, you get to take your thoughts wherever they can go and challenge yourself to find creative solutions,” he says.

“Maybe that’s not something people think about so much with science – how creative it can be – but I find in medicine, it definitely allows that for me. You have to find creative solutions, and it’s a fabulous way to feed that fire.”

Rockwell McGellin
About the author
Rockwell McGellin
Rockwell is a jack of all trades with a Masters in science communication. He likes space, beer, and sciencey t-shirts. Yes, Rocky is fine for short.
View articles
Rockwell is a jack of all trades with a Masters in science communication. He likes space, beer, and sciencey t-shirts. Yes, Rocky is fine for short.
View articles


We've got chemistry, let's take it to the next level!

Get the latest WA science news delivered to your inbox, every fortnight.


Creative Commons Logo

Republishing our content

We want our stories to be shared and seen by as many people as possible.

Therefore, unless it says otherwise, copyright on the stories on Particle belongs to Scitech and they are published under a Creative Commons Attribution-NoDerivatives 4.0 International License.

This allows you to republish our articles online or in print for free. You just need to credit us and link to us, and you can’t edit our material or sell it separately.

Using the ‘republish’ button on our website is the easiest way to meet our guidelines.


You cannot edit the article.

When republishing, you have to credit our authors, ideally in the byline. You have to credit Particle with a link back to the original publication on Particle.

If you’re republishing online, you must use our pageview counter, link to us and include links from our story. Our page view counter is a small pixel-ping (invisible to the eye) that allows us to know when our content is republished. It’s a condition of our guidelines that you include our counter. If you use the ‘republish’ then you’ll capture our page counter.

If you’re republishing in print, please email us to let us so we know about it (we get very proud to see our work republished) and you must include the Particle logo next to the credits. Download logo here.

If you wish to republish all our stories, please contact us directly to discuss this opportunity.


Most of the images used on Particle are copyright of the photographer who made them.

It is your responsibility to confirm that you’re licensed to republish images in our articles.


All Particle videos can be accessed through YouTube under the Standard YouTube Licence.

The Standard YouTube licence

  1. This licence is ‘All Rights Reserved’, granting provisions for YouTube to display the content, and YouTube’s visitors to stream the content. This means that the content may be streamed from YouTube but specifically forbids downloading, adaptation, and redistribution, except where otherwise licensed. When uploading your content to YouTube it will automatically use the Standard YouTube licence. You can check this by clicking on Advanced Settings and looking at the dropdown box ‘License and rights ownership’.
  2. When a user is uploading a video he has license options that he can choose from. The first option is “standard YouTube License” which means that you grant the broadcasting rights to YouTube. This essentially means that your video can only be accessed from YouTube for watching purpose and cannot be reproduced or distributed in any other form without your consent.


For more information about using our content, email us:

Copy this HTML into your CMS
Press Ctrl+C to copy